Roivant creates new business units, sheds and reshuffles staff

In a major restructuring, privately-held Switzerland-based  healthcare company Roivant Sciences has created two new business units, Roivant Pharma and Roivant Health, to focus its efforts on accelerating the launch of new innovative healthcare companies, including ‘Vants’ oriented around earlier-stage scientific platforms.

The news comes months after Roivant’s subsidiary Axovant imploded after the company terminated development on its lead drug intepirdine in Alzheimer's disease.

As part of this strategy, Roivant intends to make increased investments in fostering greater employee mobility across its family of companies. Select members of Roivant's staff have transitioned to existing Vants to further the advancement of their pipelines and ensure greater organizational autonomy.